Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Our RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Our diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible”, we are leading the charge toward a world in which human potential is no longer hindered by the burden of disease.

Takeda Ventures

Teva Pharmaceuticals

GlaxoSmithKline

RA Capital Management

Cormorant Asset Management

Fidelity Management and Research Company

Foresite Capital

Jennison Associates

New Leaf Venture Partners

Redmile Group

Wave Life Sciences

Vivet Therapeutics is a biotechnology company focused on developing gene therapies for inherited liver disorders.

Vivet Therapeutics

Arrowhead Pharmaceuticals is a biopharmaceutical company developing targeted RNAi therapeutics.

Arrowhead Pharmaceuticals

Antibody Analytics is a company specializing in the development of therapeutic antibodies and antibody-based therapeutics.

Antibody Analytics

XCell Science is a biotechnology company focused on developing innovative cell-based therapies for various diseases.

XCell Science

Wave Life Sciences is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for patients with serious, genetically-defined diseases. The company utilizes its proprietary chemistry platform to create next-generation nucleic acid therapeutics.

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.

Wave Life Sciences Ltd.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 14, 2024 8:29 AM	36eed495
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	d2968525
crunchbase profile	general
li profile	general	May 14, 2024 8:29 AM	5a21e0d1
translate crunchbase fundingrounds	general
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:WAVELIFESCIENCES

Wave Life Sciences

Last Close

14.35

22/11 21:00

Market Cap

682.19M

Beta: -

Volume Today

455.93K

Avg: -